Bioelectric OPG treatment of cancer
AssigneeLeonhardt Ventures LLC
InventorsHoward J. Leonhardt, Jorge Genovese
Life of this patent
Estimating the term…
Abstract
Described is a method of treating a subject diagnosed with cancer, breast cancer, bone cancer, lung cancer, osteoporosis, multiple myeloma, and a combination of any thereof by applying a bioelectric signal or signals that upregulate the expression of Osteoprotegerin (“OPG”) and thus beneficially effect the subject's OPG/RANKL/RANK pathway.
Claims12
A bioelectric stimulator programmed to produce at least one bioelectric signal that stimulate(s) target tissue of a subject to increase expression of osteoprotegerin (OPG), thus inhibiting bone degradation in the subject, wherein the bioelectric signal(s) comprise(s):
- (a) a signal of, within 15%, 4.0 milliVolt, 2,000 Hz, square wave;
- and/or
- (b) a signal of from 3 milliVolt to 5 milliVolt at a frequency range of 1 to 3 MHz, and a duration range of 30 to 40 mW/cm2 for a minimum of 20 minutes,
- wherein the bioelectric stimulator is further programmed to produce further bioelectric signal(s) that increase(s) expression of receptor activator of nuclear factor kappa-B ligand (RANKL) by the tissue, wherein the further bioelectric signal(s) comprise(s):
- (c) 3.0 mV, 2 Hz, square wave,
- (d) 3 mV at 2/100 Hz alternating frequency with current of 3 mA followed by 15 Hz, 1 Gauss EM field, consisting of 5-millisecond bursts with 5-microsecond pulses followed by 200-μs pulse duration at 30 Hz and with current amplitude of 140 mA, and/or
- (e) a biphasic pulse at 20 Hz, 0.1 V, and a 7.8 ms pulse duration.
A bioelectric stimulator programmed to produce at least one bioelectric signal that stimulates target tissue of a subject to increase expression of osteoprotegerin (OPG), thus inhibiting bone degradation in the subject, wherein the bioelectric signal comprises:
- (a) a signal of, within 15%, 4.0 milliVolt, 2,000 Hz, square wave,
- wherein the bioelectric stimulator is further programmed to produce further bioelectric signal(s) that increase(s) expression of receptor activator of nuclear factor kappa-B ligand (RANKL) by the tissue, wherein the further bioelectric signal(s) comprise(s):
- (b) 3.0 mV, 2 Hz, square wave,
- (c) 3 mV at 2/100 Hz alternating frequency with current of 3 mA followed by 15 Hz, 1 Gauss EM field, consisting of 5-millisecond bursts with 5-microsecond pulses followed by 200-μs pulse duration at 30 Hz and with current amplitude of 140 mA, and/or
- (d) a biphasic pulse at 20 Hz, 0.1 V, and a 7.8 ms pulse duration.
A bioelectric stimulator programmed to produce at least one bioelectric signal that stimulate(s) target tissue of a subject to increase expression of osteoprotegerin (OPG), thus inhibiting bone degradation in the subject, wherein the bioelectric signal(s) comprise(s):
- (a) a signal of from 3 milliVolt to 5 milliVolt at a frequency range of 1 to 3 MHz, and a duration range of 30 to 40 mW/cm2 for a minimum of 20 minutes, wherein the bioelectric stimulator is further programmed to produce further bioelectric signal(s) that increase(s) expression of receptor activator of nuclear factor kappa-B ligand (RANKL) by the tissue, wherein the further bioelectric signal(s) comprise(s):
- (b) 3.0 mV, 2 Hz, square wave,
- (c) 3 mV at 2/100 Hz alternating frequency with current of 3 mA followed by 15 Hz, 1 Gauss EM field, consisting of 5-millisecond bursts with 5-microsecond pulses followed by 200-μs pulse duration at 30 Hz and with current amplitude of 140 mA, and/or
- (d) a biphasic pulse at 20 Hz, 0.1 V, and a 7.8 ms pulse duration.
A method of using a bioelectric stimulator programmed to produce at least one bioelectric signal that stimulates target tissue in a subject to increase expression of osteoprotegerin (OPG), wherein the at least one bioelectric signal comprises:
- a signal of from 3 milliVolt to 5 milliVolt at a frequency range of 1 to 3 MHz, and a duration range of 30 to 40 mW/cm2;
- to treat a subject, the method comprising:
- delivering the at least one bioelectric signal to tissue of the subject for a minimum of 20 minutes so as to increase expression of OPG by the tissue, thus inhibiting bone degradation in the subject,
- wherein the subject has been diagnosed with a disorder selected from the group consisting of cancer, breast cancer, bone cancer, lung cancer, osteoporosis, and a combination of any thereof.
Dependencies are inferred from the claim text.